UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K
                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
                         Date of Report:  April 17, 2007

                                    VYTA CORP
                                    ---------
             (Exact name of registrant as specified in its charter)

           Nevada                  33-19598-D              84-0992908
           ------                  ----------              ----------
(State or other jurisdiction      (Commission            (IRS Employer
      of incorporation)           File Number)       Identification Number)

               370 17th Street, Suite 3640,Denver, Colorado 80202
               --------------------------------------------------
               (Address of Principal Executive Offices) (Zip Code)


                                 (303) 592-1010
                                 --------------
               Registrant's telephone number, including area code


               --------------------------------------------------
          (Former name or former address, if changed since last report)

     Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[ ]  Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))



SECTION 8 - OTHER EVENTS

ITEM 8.01 - OTHER EVENTS


      Vyta  Corp's ("the Company"), equity investment joint venture Bioagra, LLC
("Bioagra")  and  AHD  International,  LLC  ("AHD  International")  of  Atlanta,
Georgia,  signed  an  Agreement  (the  Agreement)  whereby AHD International has
agreed  to  purchase  BioAgra's  product,  AgriStim(TM).

     The  Agreement has a term of 5 years, beginning on April 1, 2007 and ending
on  March 31, 2012 with the right for successive renewals provided minimum sales
requirements are met. According to the terms of the Agreement, AHD International
will  be  purchasing AgriStim(TM) to resell the product, exclusively and in some
markets  non-exclusively  to  various  end  users  in  thirteen  countries.  AHD
International  has  exclusive  rights  to sell AgriStim(TM) in all countries for
human  consumption.  The  Agreement  does exclude certain markets and countries,
especially  the United States, where Bioagra has focused its sales and marketing
efforts,  specifically  the  poultry,  cattle,  swine  and  equine  markets. The
Agreement  does  provide  for  AHD  International  to meet certain minimum sales
requirements  in  order  to  retain  exclusivity  in any countries listed in the
Agreement.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

     (c)  EXHIBITS The following is a complete list of exhibits filed as part of
this  Report.  Exhibit numbers correspond to the numbers in the exhibit table of
Item  601  of  Regulation  S-B.

 EXHIBIT NO.                         DESCRIPTION

   99.01       Agreement by and between Bioagra, LLC and AHD International, LLC,
               dated  April  1,  2007*

____________________
*Filed  herewith


                                        2

                                   SIGNATURES

     Pursuant  to  the  requirements of the Securities Exchange Act of 1934, the
Registrant  has  duly  caused  this  Report  to  be  signed on its behalf by the
undersigned,  hereunto  duly  authorized.

                                       VYTA CORP

                                       By:   /s/ Paul H. Metzinger
                                          --------------------------------------
                                          Paul H. Metzinger, President and Chief
                                            Executive Officer

                                       Date: April 17, 2007


                                        3